The FDA has approved Pfizer’s adalimumab biosimilar, Abrilada (adalimumab-afzb), referencing Humira.
The FDA has approved Pfizer’s adalimumab biosimilar, Abrilada (adalimumab-afzb), referencing Humira.
In a statement, Sarah Yim, MD, acting director of the FDA’s Office of Therapeutic Biologics and Biosimilars in the Center for Drug Evaluation and Research, said she is pleased to see the 25th biosimilar approved in the United States, and that she is confident that the market for these products will continue to grow.
The biosimilar was studied in a 78-week, double-blind, multicenter, randomized study comparing the proposed biosimilar with EU-licensed Humira in 597 biologic-naïve patients with rheumatoid arthritis, and 26-week results of the study have been published.1
The study’s primary end point was the proportion of patients reaching the American College of Rheumatology’s criteria for 20% improvement (ACR20) at week 12, which the investigators say is a sensitive timepoint for assessment of the speed of response, as it represents the start of the plateau of the time-response curve for ACR20.
The 26-week period of initial treatment was completed by 286 patients in the biosimilar arm and 273 patients in the reference arm. In the biosimilar arm, 68.7% of patients achieved ACR20, as did 72.7% of patients in the reference arm; the treatment difference was −3.98%, which was contained within the prespecified equivalence margin of ±14%. ACR20, 50, and 70 rates were also similar through week 26 for both groups.
Despite the new FDA approval, Abrilada will not be free to launch in the US market until November 20, 2023, after Pfizer struck an agreement with Humira’s maker, AbbVie, to end patent litigation in 2018.
Abrilada joins multiple other approved but unlaunched biosimilar adalimumab products in the United States; also permitted to launch in 2023 on the basis of patent settlements are Hyrimoz (developed by Sandoz), Cyltezo (Boehringer Ingelheim), Hadlima (Samsung Bioepis), and Amjevita (Amgen).
Reference
1. Fleischmann RM, Alten R, Pileckyte M, et al. A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira) in the treatment of active rheumatoid arthritis. Arthritis Res Ther. 2018;20(1):178. doi: 10.1186/s13075-018-1676-y.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.